Navigation Links
It's all in the wrapping
Date:12/13/2011

A manmade package filled with nature's bone-building ingredients delivers the goods over time and space to heal serious bone injuries faster than products currently available, Cleveland researchers have found.

Tested on sheep in Switzerland, the surgical elastic "implant device," essentially a wrapping that mimics bone's own sock-like sheath called periosteum, delivered stem cells, growth factors and other natural components of the periosteum to heal a defect that would not heal on its own if left untreated. In experimental groups exhibiting best outcomes, a dense network of new bone filled the defect, from the surgical elastic wrapping on the outside towards the steel intramedullary nail that stabilized the bone on the inside, bridging old with new bone.

Melissa Knothe Tate, a joint professor of biomedical engineering and mechanical & aerospace engineering at Case Western Reserve University; Ulf Knothe, an orthopedic surgeon at the Cleveland Clinic, as well as Hana Chang and Shannon Moore, graduate students in Knothe Tate's lab, report their work in today's issue of PLoS ONE.

"We're trying to use the methods Mother Nature uses to generate bone," Knothe Tate said.

The device is modeled after the periosteum, the sock-like covering of bone, which is filled with stem cells and growth factors that, given the right cues, grow bone. Knothe Tate and her husband, Knothe, reported last year that bridging a bone injury with periosteum healed bone faster than any currently used methods, in testing on sheep and in limited clinical cases.

But, often there is too little of the periosteal covering left to fully cover the gap after a traumatic injury.

Based on what they'd learned, Knothe Tate built a version of periosteum out of two elastic sheets, approved by the FDA for surgery. She left one intact and perforated the other in a gradient with most holes across the center of the sheet and fewer the farther from the
'/>"/>

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-368-4442
Case Western Reserve University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Computer in wrapping-paper form
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... -- When are athletes who have suffered concussions ready ... study has found that high school athletes who head ... days experience a significant regression in their abilities to ... regression, as seen in changes in their balance and/or ... athletes. Ten of the 12 had returned to activity ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... searches blood for the tiniest remnants of broken down ... up cancer activators called proteases. The results improve researchers, ... to where to look for possible indicators of early ... , the research shows previously unknown contributing factors to ...
... The cells and tissues in our bodies grow, develop ... the various microbial pathogens that invade our bodies and ... milieu. Yet the methods of culturing and studying human ... on flat impermeable surfaces. While such 2-D culturing and ...
... with a peer facing the same self-management challenges helped ... sugar levels better than those who used traditional nurse ... University of Michigan Health System. The findings, published ... showed the peer partner program resulted in lower ...
Cached Biology News:New clues to how cancer-related proteins plasmin, thrombin lose inhibition 2New clues to how cancer-related proteins plasmin, thrombin lose inhibition 3New clues to how cancer-related proteins plasmin, thrombin lose inhibition 4The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4Diabetic adults' conditions improved after phone calls with fellow patients 2Diabetic adults' conditions improved after phone calls with fellow patients 3
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... the enterprise replication cluster, faster loading speeds, higher ... Elasticsearch. This release happens to coincide with a ... GraphDB™ was formerly known as OWLIM. ... enterprise resilient RDF triplestore will also benefit from ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who have ... rituximab-containing,regimen. According to the National Cancer Institute, an ...
... MYL ) today,announced that Mylan Pharmaceuticals Inc. ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Balsalazide Disodium Capsules are the generic version of ... approximately,$130.9 million for the 12 months ending Sept. ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4